Document is current
Any future updates will be listed below
-
Authors
van Amstel, Rombout B. E.
Slim, Marleen A.
Lim, Endry H. T.
Rückinger, Simon
Seymour, Christopher W.
Burnett, Bruce P.
Bos, Lieuwe D. J.
van Vught, Lonneke A.
Riedemann, Niels C.
van de Beek, Diederik
Vlaar, Alexander P. J.
,
Witzenrath, Martin
van Paassen, Pieter
Heunks, Leo M. A.
Mourvillier, Bruno
de Bruin, Sanne
Brouwer, Matthijs C.
Tuinman, Pieter R.
Saraiva, José Francisco K.
Marx, Gernot
Lobo, Suzana M.
Boldo, Rodrigo
Simon-Campos, Jesus A.
Cornet, Alexander D.
Grebenyuk, Anastasia
Engelbrecht, Johannes M.
Mukansi, Murimisi
Jorens, Philippe G.
Zerbib, Robert
Pilz, Korinna
Guo, Renfeng
Bulpa, Pierre
Taccone, Fabio S.
Hermans, Greet
Diltoer, Marc
Piagnerelli, Michael
De Neve, Nikolaas
Freire, Antonio T.
Pizzol, Felipe D.
Marinho, Anna Karolina
Sato, Victor H.
da Cunha, Clovis Arns
Neuville, Mathilde
Dellamonica, Jean
Annane, Djillali
Roquilly, Antoine
Diehl, Jean Luc
Schneider, Francis
Mira, Jean Paul
Lascarrou, Jean Baptiste
Desmedt, Luc
Dupuis, Claire
Schwebel, Carole
Thiéry, Guillaume
Gründling, Matthias
Berger, Marc
Welte, Tobias
Bauer, Michael
Jaschinski, Ulrich
Matschke, Klaus
Mercado-Longoria, Roberto
Quintana, Belinda Gomez
Zamudio-Lerma, Jorge Alberto
Abril, Juan Moreno Hoyos
Marquez, Angel Aleman
Pickkers, Peter
Otterspoor, Luuk
Vásquez, Luis Hercilla
Ramos, Carlos Rafael Seas
Villalobos, Alejandro Peña
Malca, Gonzalo Gianella
Chávez, Victoria
Filimonov, Victor
Kulabukhov, Vladimir
Acharya, Pinak
Timmermans, Sjoerd A. M. E. G.
Busch, Matthias H.
van Baarle, Floor L. F.
Koning, Rutger
ter Horst, Liora
Chekrouni, Nora
van Soest, Thijs M.
van Amstel, Rombout B. E.
Olie, Sabine E.
van Zeggeren, Ingeborg E.
van de Poll, Marcel C. G.
Thielert, Claus
Neukirchen, Dorothee
- License Information
-
More Information
Article History
Received: 25 April 2024
Accepted: 25 June 2024
First Online: 28 June 2024
Declarations
:
: The study protocol of the phase 3 PANAMO trial was approved by the institutional review board (Amsterdam UMC, Amsterdam, Netherlands; IRB 2020_067#B2020179). The trial was approved by the institutional review boards or ethics committees and conducted according to the Declaration of Helsinki and Good Clinical Practise guidelines. Written informed consent was provided by all patients or their legally authorised representatives. In the Netherlands, Germany and Russia, deferred consent was allowed if direct informed consent of patients’ legally authorised representatives was not possible, followed by deferred patient or patients’ representatives consent (deferred proxy consent).
: SR is an employee of Metronomia Clinical Research and a contracted statistical service provider for InflaRx. BPB is an employees of InflaRx and may hold shares and/or stock options in InflaRx. LDJB received consultancy fees from Scailyte, Santhera and Janssen en Janssen, and was on the advisory board of Sobi, Exvastat, Pfizer and Astra Zeneca, all paid to the institution. NCR is founder, active officer, and executive director of the board, and holds shares and stock options in InflaRx. APJV received consulting fees from InflaRx for advisory work, paid to the institution. The other authors have no competing interests.
